Pfizer (PFE) is an interesting stock to follow. Apart from being a great dividend stock, the company also boasts of a diversified portfolio, strong free cash flow, and consistency in beating earnings expectations. Let’s quickly take a look at the pros and cons. https://news.alphastreet.com/pfizer-this-year-headwinds-and-tailwinds/ Tailwinds Pfizer is undoubtedly one of the best dividend stocks, thanks to its strong cash reserves. For the company, dividends have always taken a top priority in the capital allocation program. Apart from the 3.8% dividend yield, what makes the company a safe drug stock is the strong performance of its new drugs. Headwinds Pfizer’s plans to jettison its lackluster consumer health unit went sour after all the potential buyers dropped out of the bidding process. The company was planning to raise $20 billion through the sale, but the buyers found the deal overvalued. So for now, Pfizer will probably have to hang on with this unit for a little while longer.
the headwinds is LOE. Revenue will continue to decline. Tailwinds is time because Pfizer is moving beyond LOE revenue losses. Also, new drug development is producing.
